Clinical research solutions provider Celerion has deployed the Verified Clinical Trials (VCT) biometric fingerprint technology to prevent dual enrolment in clinical trials.
The technology utilises a fingerprint biometrics and ID metric hybrid process to avoid simultaneous multiple clinical drug trial enrolment or premature re-enrolment into another study.
VCT also provides a HIPAA compliant research subject clinical trials database registry to improve both patient safety and preserve data integrity in clinical trials.
Celerion global clinical research vice-president Phil Bach said: “Our focus has always been to help our clients get their drugs to market and protect the safety and well-being of our participants. The VCT database registry enhances our ability to achieve both of those objectives.
“Celerion and VCT share the same vision of applying scientific expertise and advanced technology to ensure the safety of our participants and maintain data integrity, leading to successful clinical trial outcomes.”
Celerion has performed approximately 50,000 verifications over the last five years, using the VCT database registry to identify subjects that are already enrolled in other clinical trials.
With the implementation of VCT’s biometric fingerprint technology, the firm intends to bolster the accuracy and speed of the verifications performed at the facilities.
VCT chief executive officer Kerri Weingard said: “By joining forces five years ago, Celerion and VCT led the way in providing a solution that maximises detection of attempted duplicate enrolment and protocol violations.
"This combined effort raised awareness and utilisation across all phases of clinical research, highlighting the need for a research subject database in the clinical trials industry."